Literature DB >> 21616491

Genetic and environmental regulation of inflammatory CVD biomarkers Lp-PLA2 and IgM anti-PC.

Iffat Rahman1, Rajai Atout, Nancy L Pedersen, Ulf de Faire, Johan Frostegård, Ewa Ninio, Anna M Bennet, Patrik K E Magnusson.   

Abstract

OBJECTIVE: We set out to investigate the relative contribution of genetic and environmental effect on two inflammatory CVD biomarkers; lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and anti-phosphorylcholine IgM (anti-PC). Their relationships and possible co-regulation with other established CVD biomarkers are also examined.
METHODS: Lp-PLA(2) activity (N=1600) and anti-PC (N=2036) levels were measured in elderly Swedish twins. Correlation analyses and heritability estimation were conducted by structural equation modeling.
RESULTS: We attribute 0.37 of the variance of Lp-PLA(2) and 0.40 of anti-PC variance to genetic variance. In addition, a bivariate heritability of 0.33, 0.35 and 0.36 could be detected for levels of Lp-PLA(2) together with ApoB, total cholesterol and LDL, respectively. Anti-PC was only weakly related to other biomarkers of CVD, which may suggest a more independent role of anti-PC as a biomarker.
CONCLUSIONS: In this large sample, Lp-PLA(2) activity has lower heritability and higher environmental regulation than previously reported. Anti-PC levels are partly influenced by dominance genetics and appear to be regulated independently of more established CVD biomarkers.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21616491     DOI: 10.1016/j.atherosclerosis.2011.04.038

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

Review 1.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

2.  Low levels of a natural IgM antibody are associated with vein graft stenosis and failure.

Authors:  Michael Sobel; Katherine I Moreno; Mayumi Yagi; Ted R Kohler; Gale L Tang; Alexander W Clowes; Xiao-Hua A Zhou; Evercita Eugenio
Journal:  J Vasc Surg       Date:  2013-07-13       Impact factor: 4.268

3.  A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia.

Authors:  Xu Chen; Stefan Gustafsson; Thomas Whitington; Yan Borné; Erik Lorentzen; Jitong Sun; Peter Almgren; Jun Su; Robert Karlsson; Jie Song; Yi Lu; Yiqiang Zhan; Sara Hägg; Per Svensson; Karin E Smedby; Susan L Slager; Erik Ingelsson; Cecilia M Lindgren; Andrew P Morris; Olle Melander; Thomas Karlsson; Ulf de Faire; Kenneth Caidahl; Gunnar Engström; Lars Lind; Mikael C I Karlsson; Nancy L Pedersen; Johan Frostegård; Patrik K E Magnusson
Journal:  Hum Mol Genet       Date:  2018-05-15       Impact factor: 6.150

Review 4.  Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease.

Authors:  Caroline Grönwall; Gregg J Silverman
Journal:  J Clin Immunol       Date:  2014-04-02       Impact factor: 8.317

5.  Quantile-Specific Heritability of Inflammatory and Oxidative Stress Biomarkers Linked to Cardiovascular Disease.

Authors:  Paul T Williams
Journal:  J Inflamm Res       Date:  2022-01-05

Review 6.  Immunity, atherosclerosis and cardiovascular disease.

Authors:  Johan Frostegård
Journal:  BMC Med       Date:  2013-05-01       Impact factor: 8.775

Review 7.  Immune mechanisms in atherosclerosis, especially in diabetes type 2.

Authors:  Johan Frostegård
Journal:  Front Endocrinol (Lausanne)       Date:  2013-10-29       Impact factor: 5.555

8.  Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.

Authors:  Sofia Ajeganova; Maria L E Andersson; Johan Frostegård; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2021-07-27       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.